Overview

Orexigenic Therapy With Delta-9-tetrahydrocannabinol in Advanced Cancer Patients With Chemosensory Abnormalities - a Pilot Study

Status:
Completed

Trial end date:
2009-11-01

Target enrollment:

Participant gender:

Summary

To investigate delta-9-tetrahydrocannabinol's (THC) ability to increase food intake and improve food enjoyment for advanced cancer patients with taste and/or smell (chemosensory) abnormalities.

Phase:

Phase 2

Details

Lead Sponsor:

Alberta Health Services

Collaborator:

University of Alberta

Treatments:

Dronabinol